The two companies have been working together since 2017, with Takeda pledging $100 million to help GammaDelta advance its cell therapy platform as part of a "build-to-buy" arrangement. The ...
Takeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn's disease, becoming the first allogeneic stem cell therapy to be approved in Japan.
Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...
News Medical on MSN3d
Are Allogeneic CAR-Ts the Future of LBCL Cancer Treatment? - Making Safe, Durable & Effective Universal Cell Therapies a RealityAllogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T 'Cemacabtagene Ansegedleucel/ALLO-501' in Relapsed/Refractory Large B-Cell ...
GlobalData on MSN9d
Takeda broadens its deal with BridGene for up to $770mTakeda will pay $46m upfront to leverage BridGene’s chemoproteomics platform, dubbed IMTAC. The platform screens small ...
Takeda and Protagonist Therapeutics have reported ... demonstrating a significant increase in clinical responders in the therapy arm, with 77% of these subjects achieving an absence of phlebotomy ...
Takeda has returned to BridGene Biosciences ... to analyze interactions between small molecules and proteins in living cells. While most drugs form reversible bonds with targets, the history ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback